Microvillous inclusion disease – Diagnostics – Overview of Information and Clinical Research

Microvillus inclusion disease is a rare genetic condition affecting the intestine that leads to severe, life-threatening diarrhea beginning in the earliest days of life, making it impossible for affected infants to absorb essential nutrients and fluids from food.

Introduction: When to Seek Diagnostic Evaluation

Diagnosing microvillus inclusion disease begins with recognizing when a newborn or infant needs medical evaluation. Parents and caregivers should seek immediate medical attention if their baby develops severe, watery diarrhea within the first hours or days after birth. This type of diarrhea is unusual because it does not improve even when feeding stops completely, which is a key warning sign that something serious may be affecting the intestine.^[1]

In some cases, symptoms may not appear immediately after birth but can develop when the baby is around two to four months old. These later-onset cases may present with somewhat less severe symptoms, though the diarrhea remains serious and persistent. The amount of fluid lost through diarrhea in affected infants can be enormous—sometimes reaching volumes similar to what is seen in cholera. Babies can lose up to 30 percent of their body weight within just 24 hours, leading to dangerous dehydration and metabolic problems.^[4]

Any infant who shows signs of failure to thrive, meaning they are not gaining weight as expected, along with persistent watery diarrhea and signs of dehydration should undergo diagnostic testing. Because microvillus inclusion disease is so rare and potentially life-threatening, early diagnosis is critical. The condition requires specialized care, ideally at medical centers with expertise in rare intestinal disorders and access to advanced diagnostic tools.^[3]

⚠️ Important

Because microvillus inclusion disease can cause infants to lose such massive amounts of fluid so rapidly, immediate medical attention is essential when severe diarrhea appears in newborns. Without prompt intravenous hydration and nutritional support, the condition can quickly become life-threatening due to severe dehydration and metabolic imbalances.

Classic Diagnostic Methods

The diagnostic process for microvillus inclusion disease involves multiple steps, beginning with initial clinical assessment and progressing to specialized tissue analysis. The first step typically involves doctors evaluating the type of diarrhea and determining which nutrients the baby cannot absorb. This initial assessment helps doctors understand the severity of the problem and rule out other more common causes of infant diarrhea.^[1]

Endoscopy and Biopsy Collection

When doctors suspect a congenital diarrhea—meaning a diarrhea condition present from birth—they need to examine tissue from the small intestine directly. To obtain this tissue, they perform a procedure called an endoscopy. During this procedure, doctors use a small, flexible viewing tube that allows them to look inside the intestine and collect tiny tissue samples called biopsies. This procedure is essential because the definitive diagnosis of microvillus inclusion disease can only be made by examining these intestinal tissue samples.^[1]

The endoscopy procedure requires careful planning and preparation, especially when performed on very young infants who are already medically fragile. Because patients with microvillus inclusion disease rarely undergo repeat endoscopies after their initial diagnosis, obtaining adequate tissue samples during the first procedure is particularly important.^[9]

Light Microscopy Examination

Once tissue samples are collected, they undergo examination under a regular microscope, known as light microscopy. Under light microscopy, the intestinal tissue from babies with microvillus inclusion disease shows several characteristic features. Doctors look for an accumulation of special staining material at the top portion of immature intestinal cells. This material appears positive when stained with a technique called PAS staining, which stands for periodic acid-Schiff staining.^[3]

The tissue also shows what doctors describe as an “atrophic band,” indicating that the microvilli—the tiny finger-like projections that normally cover the surface of intestinal cells—have wasted away or failed to develop properly. Additionally, there is an intracellular line that stains positive with PAS or with a marker called CD10. This line marks the presence of abnormal structures inside the cells that contain microvilli, which should normally be on the outside surface of the cells.^[3]

The appearance of microvillus inclusion disease under light microscopy can look somewhat similar to another condition called celiac disease. However, microvillus inclusion disease typically lacks the increased number of certain immune cells that characterize celiac disease. The tissue also shows positive staining for a protein marker called carcinoembryonic antigen (CEA), which helps distinguish it from celiac disease.^[5]

Electron Microscopy: The Gold Standard

The definitive diagnosis of microvillus inclusion disease depends on examination using a special type of microscope called an electron microscope. This highly powerful microscope can reveal details that are impossible to see with regular light microscopy. Electron microscopy is considered the gold standard for diagnosing this condition because it can identify the distinctive cellular abnormalities that define the disease.^[1]

Using electron microscopy, doctors can detect two main features that are characteristic of microvillus inclusion disease. The first is a partial or complete loss of the microvilli on mature intestinal cells, called enterocytes. In healthy intestines, these microvilli cover the cell surface like a dense brush, which is why this area is sometimes called the “brush border.” In microvillus inclusion disease, this brush border is severely reduced or entirely absent.^[3]

The second hallmark feature visible on electron microscopy is the presence of highly characteristic structures called microvillus inclusion bodies within the cytoplasm of mature enterocytes. These are abnormal compartments inside the cells that contain rudimentary or fully formed microvilli that should be on the cell surface, not trapped inside. This finding is so distinctive that it gave the disease its name.^[7]

In immature enterocytes, electron microscopy also reveals an accumulation of numerous secretory granules at the top portion of the cells. These granules are another sign that the normal development and function of the intestinal cells has been disrupted.^[3]

Genetic Testing

Molecular genetic testing has become an essential component of the diagnostic process for microvillus inclusion disease. After obtaining tissue samples and performing microscopy, doctors will conduct genetic testing to look for mutations in the genes known to cause this condition. The main gene associated with microvillus inclusion disease is called MYO5B, which provides instructions for making a protein called myosin Vb. This protein plays a crucial role in determining the proper organization and positioning of various components within intestinal cells.^[2]

Mutations in the MYO5B gene that cause microvillus inclusion disease result in a decrease or complete absence of functional myosin Vb protein. In intestinal cells, the lack of this protein disrupts normal cell organization, preventing enterocytes from properly forming microvilli on their surface. Instead, these microvilli become trapped inside the cells, forming the characteristic inclusion bodies.^[2]

In addition to MYO5B, mutations in other genes can also cause microvillus inclusion disease or variant forms of the condition. These include mutations in the STX3 gene (syntaxin 3), the STXBP2 gene (also called Munc18-2), and the UNC45A gene. Some cases involve variants without detectable microvillus inclusions but with similar clinical symptoms. Identifying the specific genetic mutation is important because it helps confirm the diagnosis, provides information about inheritance patterns for families, and may eventually help guide treatment decisions.^[4]

Genetic testing also allows for prenatal diagnosis in families where the specific mutation has already been identified in an affected child. However, because microvillus inclusion disease is so rare and does not typically cause specific prenatal symptoms, prenatal diagnosis is only possible when families already know they carry the genetic mutations.^[4]

Distinguishing from Other Conditions

An important part of the diagnostic process involves distinguishing microvillus inclusion disease from other rare conditions that can cause similar symptoms. The differential diagnosis includes several other rare congenital enteropathies that present with severe, persistent diarrhea in infants. These include autoimmune enteropathy, where the immune system attacks the intestine; chloride diarrhea and congenital sodium diarrhea, which involve problems with how the intestine handles salt; and congenital tufting enteropathy, another genetic disorder affecting the intestinal lining.^[4]

Doctors must also consider other conditions that cause chronic diarrhea in infants, such as intestinal epithelial dysplasia, syndromatic diarrhea, and immunoinflammatory enteropathy. Each of these conditions has distinct features visible on biopsy and different genetic causes. Accurate diagnosis is crucial because the management and prognosis can differ significantly between these conditions.^[5]

Diagnostic Criteria for Clinical Trial Enrollment

For patients with microvillus inclusion disease who may be considered for enrollment in clinical trials testing new treatments, specific diagnostic criteria must be met. Clinical trials typically require confirmation of the diagnosis through multiple methods to ensure that participants truly have the condition being studied and that the trial results will be meaningful and accurate.

Most clinical trials for microvillus inclusion disease require documented evidence of the characteristic findings on electron microscopy showing microvillus atrophy and the presence of microvillus inclusion bodies in enterocytes. This histological confirmation is considered essential because it provides the most definitive proof of the disease at the cellular level.^[3]

Additionally, clinical trials usually require genetic confirmation through molecular testing showing mutations in one of the known disease-causing genes, most commonly MYO5B. Having both the microscopic evidence and the genetic evidence strengthens the diagnostic certainty and helps researchers understand which genetic variants respond to specific treatments. Some trials may focus specifically on patients with particular genetic mutations, making genetic testing results a key enrollment criterion.^[4]

Clinical trials may also establish specific criteria regarding the patient’s clinical history and current status. This might include documentation of when symptoms first appeared, the severity and persistence of diarrhea, the patient’s dependence on parenteral nutrition (intravenous feeding), and the absence of other conditions that could explain the symptoms. Researchers developing treatments for microvillus inclusion disease often use patient-derived intestinal organoids—laboratory-grown miniature intestines created from patients’ own stem cells—to study the disease and test potential therapies. Patients participating in such research may need to undergo additional biopsies to provide tissue for creating these organoids.^[9]

⚠️ Important

Families considering clinical trial participation should understand that diagnostic requirements for trials may be more extensive than those needed for clinical care alone. Trials may require fresh tissue samples, detailed genetic analysis of specific genes, or creation of patient-derived organoids. These additional procedures are conducted to advance scientific understanding and develop better treatments for all patients with microvillus inclusion disease.

For trials testing medications that aim to reduce diarrhea or improve nutrient absorption, baseline measurements of stool output, hydration status, nutritional markers, and growth parameters are typically required. These baseline measurements allow researchers to accurately assess whether the treatment being tested produces meaningful improvements. Patients may need to undergo regular monitoring of blood tests, stool volume measurements, and nutritional assessments throughout the trial period.^[10]

Some research studies, particularly those investigating new treatments targeting the root cause of microvillus inclusion disease, may require evidence of the specific cellular and molecular defects that characterize the condition. This might include demonstration of abnormal protein localization within intestinal cells, disrupted cell polarity, or specific defects in electrolyte transport. These detailed characterizations help researchers determine which patients are most likely to benefit from targeted therapies.^[9]

Prognosis and Survival Rate

Prognosis

The long-term outlook for children with microvillus inclusion disease has improved significantly over recent decades, though the condition remains extremely serious and life-altering. Historically, the prognosis was very poor, with approximately 50 percent of children with microvillus inclusion disease dying before reaching two years of age. This grim outlook was primarily due to complications related to severe malnutrition, repeated episodes of life-threatening dehydration, metabolic decompensation, and infections.^[9]

Advances in parenteral nutrition—the delivery of nutrients directly into the bloodstream through intravenous feeding—have transformed microvillus inclusion disease from an almost universally fatal condition into a manageable, though challenging, chronic disease. With appropriate long-term parenteral nutrition, many children can now survive well beyond infancy and grow into adolescence and adulthood. However, quality of life remains significantly affected, as patients require daily intravenous nutrition and face frequent hospitalizations for dehydration and infections.^[9]

The prognosis varies somewhat between the early-onset form, which develops within hours or days of birth, and the late-onset form, which appears around three to four months of age. The late-onset form tends to be somewhat less severe, and some patients with this variant may achieve partial oral absorption and may not require full-time parenteral nutrition. Individuals with the variant type more frequently survive past childhood.^[2]

Long-term complications significantly affect prognosis and quality of life. Prolonged dependence on parenteral nutrition can lead to serious liver problems, including cholestasis—a reduced ability to produce and release bile—which can progress to irreversible liver disease known as cirrhosis. Other potential complications include kidney problems, thinning of the bones called osteoporosis, developmental delays, and recurrent infections related to the central line used for intravenous feeding. These complications can become life-threatening and often determine whether a patient will need to consider intestinal transplantation.^[2]

Intestinal transplantation offers the possibility of intestinal autonomy—the ability to function without parenteral nutrition—and represents a potential cure for the intestinal manifestations of microvillus inclusion disease. When performed early and successfully, intestinal transplantation can dramatically improve outcomes and quality of life. However, transplantation carries its own significant risks and requires lifelong immunosuppression to prevent rejection of the transplanted organ. Some patients may require both intestinal and liver transplantation if liver disease has already developed from long-term parenteral nutrition.^[3]

Factors that influence prognosis include the timing of diagnosis, access to specialized care at centers experienced in managing rare intestinal disorders, the specific genetic mutation involved, the development of complications from parenteral nutrition, and access to intestinal transplantation when needed. Children who are diagnosed promptly and managed at specialized centers generally have better outcomes than those whose diagnosis is delayed or who receive care at facilities without expertise in this rare condition.^[3]

Recent research advances offer new hope for improving prognosis. Scientists have successfully created laboratory models of the disease using patient-derived organoids and have identified potential treatments that could address the root causes of microvillus inclusion disease. Clinical trials are beginning to test medications that might reduce diarrhea or even restore some intestinal function. While these treatments are still experimental, they represent the first potential disease-modifying therapies beyond supportive care and transplantation.^[9]

Survival Rate

Specific survival rate statistics for microvillus inclusion disease are difficult to establish with precision because the condition is so rare, with fewer than 200 cases reported in Europe and only a few hundred cases documented worldwide. Additionally, survival rates have changed dramatically over time as medical management has improved, making older statistics less relevant to current patient outcomes.^[4]

Historical data indicated that approximately half of children with microvillus inclusion disease died before their second birthday. These deaths typically resulted from metabolic complications, severe dehydration, infections, or liver failure related to parenteral nutrition dependency. However, these statistics reflect outcomes from an era before current advances in nutritional support and specialized care became available.^[9]

Modern survival rates have improved substantially with advances in parenteral nutrition and specialized care at expert centers. Children who receive optimal supportive care from diagnosis through childhood can now survive into adolescence and adulthood. Some patients have lived for 20, 30, or even 40 years while dependent on parenteral nutrition, demonstrating that long-term survival is possible with appropriate management. Two sisters with microvillus inclusion disease were documented as being 36 and 28 years old, representing the oldest known living patients with the condition who had not required intestinal transplantation.^[20]

Survival outcomes are generally better for patients with the late-onset form of microvillus inclusion disease compared to those with the early-onset form. The variant form of the disease, which presents with milder diarrhea and may not require full-time parenteral nutrition, has a more favorable prognosis, with many affected individuals living past childhood.^[2]

For patients who undergo successful intestinal transplantation, survival outcomes depend on multiple factors including the timing of transplantation, whether liver transplantation is also needed, the patient’s overall health status at the time of transplant, and the quality of post-transplant care and immunosuppression management. Early intestinal transplantation resulting in intestinal autonomy offers new hope for improved survival and quality of life.^[3]

It is important to note that while medical advances have made microvillus inclusion disease survivable, the condition remains life-altering and requires intensive ongoing medical management. Long-term survival depends critically on access to specialized care, prevention and management of complications, and for many patients, eventual consideration of intestinal transplantation. Families should work closely with expert centers that have experience managing this rare condition to optimize outcomes.^[3]

#1 Clinical Trials Search in Europe